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1. Introduction
AQ3
What is visual acuity? Why do we measure it? How should we
measure it?
10 I suspect if you were to ask these questions to a hundred
different ophthalmic professionals, you would receive a hun-
dred different answers. Since the advent of letter acuity charts
by Snellen more than 150 years ago, their ease of understand-
ing by patients, short test duration, and the fact that they
15 actually measure residual visual function mean that letter acuity
testing will likely continue to occupy a prime position in the
increasing battery of tests available to assess ocular status.
But have we done all we can to optimize the diagnostic
ability of this much-used test of visual function?
20 2. Background
The term acuity refers to sharpness or keenness of some kind.
The problem with this definition is that, unlike a metric such as
body weight, patients do not possess an intrinsic value for
‘acuity’ and the value is very much dependent on both the
25 acuity target and task.
It is well accepted that acuity values are different for grating
and letter acuity [1–3], with the number of cycles in a grating
target [4], between Snellen and logMAR acuity [5], between
Snellen and Landolt C acuity [6], and with different number of
30 alternative letter choices and what they are [7]. Thus, when
recording the ‘acuity’ value for a particular patient, it is essential
to indicate that it refers to acuity for a particular acuity chart
design, with any comparisons between acuity results from dif-
ferent charts not always being a trivial matter. This is commonly
35 appreciated when changing from picture optotypes to letter
optotypes in pediatric patients for example.
Thibos and Bradley [8] defined three types of acuity task,
forming different levels of an acuity pyramid. These they
successively named detection acuity, resolution acuity, and
40 recognition acuity. The most basic detection acuity task merely
requires the patient to determine the presence or absence of
some form of contrast against a background of the same
average luminance. This type of task is employed in acuity
tests such as preferential looking when the patient is perhaps
45 asked, ‘Is the target on the right or the left of the chart?’ No
further feedback about the stimulus is required. On the other
hand, resolution acuity requires a higher level of discrimination
in that the patient must, for example, report whether the bars
of the grating are horizontal or vertical. This type of task
50usually employs a small number of choices (alternatives)
between targets that are quite different from each other. The
highest level of the Thibos and Bradley pyramid, recognition
acuity, requires some form of identity determination by the
patient, usually from a larger number of alternatives, and
55requiring more cognitive input in the task.
Thibos and Bradley pointed out that, in the normal visual
system, foveal acuity of all three types is largely determined by
optical factors (refractive error, diffraction, and higher order
aberrations) affecting the base layer of the pyramid (detection)
60in that spatial frequencies that manage to pass through the
optics of the eye are well within the resolving power of the
retinal receptors. Only when retinal cell density declines sig-
nificantly does recognition acuity switch to become depen-
dent on neural rather than optical factors.
65Thibos and Bradley point out that conventional letter acuity
charts test at the top of the pyramid (recognition) in that they
require the patient to identify the letter without any further
information about previous stages. The advantage of this is
that the test is quick, and a good performance means that the
70patient’s visual system is performing well as a ‘black box.’©
However, when acuity declines it is not possible to determine
at which level the system failed. Is it because declining optical
quality renders the contrast too low for detection, or because the
density of the retinal cells is too depleted to permit good resolu-
75tion? Detection acuity may actually remain unaffected but can-
not properly be measured with conventional black-on-white
letter charts because of the large difference in mean luminance
between the letters and the background. It is known that
patients with age-related macular degeneration (AMD) display
80different detection and recognition thresholds [9] but we have
no way of knowing with conventional acuity charts.
3. The Moorfields Acuity Chart
The Moorfields Acuity Chart (MAC) was initially designed to
improve the test-retest variability (TRV) that limits the clinical
85monitoring ability of conventional acuity charts, both in
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normal subjects [10,11] and especially in subjects with eye
disease [9,12–14]. Because of this variability, clinical trials typi-
cally require a change of three logMAR lines (15 letters) to
indicate a significant change in visual acuity.
90 One factor that our group identified as a significant source of
acuity measurement variability was the hugely varying spatial
frequency content of the letters employed on conventional charts,
particularly in the low frequencies that form thebasic ‘shape’of the
letters. Thus, some letters remain easily identified by their overall
95 shape long after the frequency of their individual strokes, com-
monly considered to be five strokes per letter, has exceeded the
resolution limit [2,3]. We hypothesized that the large differences in
letter legibility owing to the differing low frequency content often
resulted in the within-line differences in legibility being greater
100 that the between-line differences. If we removed the low fre-
quency content of letters they shouldbecomemore equally similar
and TRV should reduce.
The MAC is the result of this idea. It employs ‘high-pass’
letters, preserving the high frequency content that forms the
105 ‘edges’ of the letters, and removing the low frequency content
where large between-letter differences lie. The letters, con-
structed from black and white lines on a gra©y background of
the same mean luminance (see Figure 1), have also been
label©ed ‘vanishing optotypes’ in that, for normal foveal vision,
110 the detection and recognition thresholds for these letters are
very similar and the letter is observed to disappear soon after
the recognition limit has been reached.
Interestingly, in peripheral vision, the thresholds display
very different detection and recognition thresholds [15]
115because recognition acuity outside the fovea is known to be
determined by the previously©mentioned lower retinal sam-
pling density, rather than optical quality [16–18].
The MAC has been shown to not only reduce TRV over ETDRS AQ4
charts [7,19]©but also to possess higher sensitivity to early©AMD©[9].
120Based on a retinal sampling simulation, Shah et al. [9] proposed
that this is because recognition of the high-pass letters is more
vulnerable to cell drop out than conventional black-on-white let-
ters. Interestingly, the same simulation showed that cell under-
sampling resulted in the letters remaining detectable long after
125they could no longer be recognized. The same study found that, as
AMD progressed, the letters no longer displayed equal detection
and recognition acuity but recognition acuity fell sharply while
detection remained much more stable. This means that, for these
letters, foveal vision in early AMD becomes more like peripheral
130visionwhich is known tobe limitedby retinal cell samplingdensity.
4. Discussion
So, what is the clinical relevance of these observations? For too
long conventional visual acuity has acted as a ‘one size fits all’ test
of functional vision, with little or no diagnostic ability in and of
135itself. Acuity using conventional letters is affected by both neural
and optical losses of vision to differing degrees depending on the
condition and its stage of development. This limits the diagnostic
ability of the test in early stage disease and its power to differ-
entiate the various factors contributing to loss of function. The
140©MAC has been shown to display better repeatability and high
Figure 1. Appearance of the Moorfields Acuity Chart.
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sensitivity to conditions like early AMD but it may also hold
potential to improve the separation of neural and optical losses
of vision in a way that is quick and easy for the patient to under-
stand. Modern number-of-letters scoring methods could be
145 employed to separately measure the detection and recognition
components of Bradley and Thibos’ acuity pyramid. In the former
the patient is asked to count the number of letters s\he can ‘see.’©In
the latter s\he is asked to (more conventionally) read the letters
until errors are made. The ratio of ‘letters read’ to ‘letter detected’
150 is an indicator of the extent to which ‘acuity’ is limited at the
optical contrast detection stage rather than the neural resolution
stage. A normal visual system should display a ratio close to©1. A
patient with early AMD would display a ratio significantly lower
than©1. As disease progresses further both values may suffer more
155 equally and the ratio change yet again. Patients with diseases that
cause loss of contrast in the neural image (e.g. optic neuritis) may
display a parallel decline in bothmeasures indicating that recogni-
tion acuity is limited by the lower contrast detection base of the
pyramid. Future electronic versions of the chart may better facil-
160 itate the separate measurement of these different thresholds and
subsequent scoring, and this is under development.
Visual acuity measurement shows no signs of declining as a
functional test of vision. It is perhaps time we sought to better
exploit its diagnostic potential in the interests of better patient
165 management.
Funding
Research work has been funded by NIHR, Moorfields Eye Charity and Fight
for Sight (UK).AQ5
Declaration of interest
170 RS Anderson has received funding from the NIHR, The Macular Society,
Fight for Sight and Moorfields Eye Charity. The authors have no other
relevant affiliations or financial involvement with any organization or
entity with a financial interest in or financial conflict with the subject
matter or materials discussed in the manuscript apart from those dis-
175 closed. Peer reviewers on this manuscript have no relevant financial or
other relationships to disclose.
References
1. Genter CR 2nd, Kandel GL, Bedell HE. The minimum angle of
resolution vs angle of regard function as measured with different
180 targets. Ophthalmic Physiol Opt. 1981;1:3–12.AQ6
AQ7
2. Anderson RS, Thibos LN. Sampling limits and critical bandwidth for
letter discrimination in peripheral vision. J Opt Soc Am A.
1999;16:2334–2342.
3. Bondarko VM, Danilova MV. What spatial frequency do we use to
185detect the orientation of a Landolt C? Vision Res. 1997;37:2153–
2156.
4. Anderson RS, Evans DW, Thibos LN. Effect of window size on
detection acuity and resolution acuity for sinusoidal gratings in
central and peripheral vision. J Opt Soc Am A. 1996;13:697–706.
1905. Falkenstein IA, Cochran DE, Azen SP, et al. Comparison of visual
acuity in macular degeneration patients measured with snellen and
early treatment diabetic retinopathy study charts. Ophthalmology.
2008;115:319–323.
6. Grimm W, Rassow B, Wesemann W, et al. Correlation of optotypes
195with the Landolt ring–a fresh look at the comparability of opto-
types. Optom Vis Sci. 1994;71:6–13.
7. Shah N, Dakin SC, Redmond T, et al. Vanishing optotype acuity:
repeatability and effect of the number of alternatives. Ophthalmic
Physiol Opt. 2011;31:17–22.
2008. Thibos LN, Bradley A. New methods for discriminating neural and
optical losses of vision. Optom Vis Sci. 1993;70:279–287.
9. Shah N, Dakin SC, Dobinson S, et al. Visual acuity loss in patients
with age related macular degeneration, measured using the
Moorfields Acuity Chart. Br J Ophthalmol. 2016;100:1346–1352.
20510. Rosser DA, Cousens SN, Murdoch IE, et al. How sensitive to clinical
change are ETDRS logMAR visual acuity measurements? Invest
Ophthalmol Vis Sci. 2003;44:3278–3281.
11. Rosser DA, Murdoch IE, Cousens SN. The effect of optical defocus
on the test-retest variability of visual acuity measurements. Invest
210Ophthalmol Vis Sci. 2004;45:1076–1079.
12. Blackhurst DW, Maguire MG. Reproducibility of refraction and
visual acuity measurement under a standard protocol. The macular
photocoagulation study group. Retina. 1989;9:163–169.
13. Kiser AK, Mladenovich D, Eshraghi F, et al. Reliability and consis-
215tency of visual acuity and contrast sensitivity measures in advanced
eye disease. Optom Vis Sci. 2005;82:946–954.
14. Beck RW, Moke PS, Turpin AH, et al. A computerized method of
visual acuity testing: adaptation of the early treatment of diabetic
retinopathy study testing protocol. Am J Ophthalmol.
2202003;135:194–205.
15. Shah N, Dakin SC, Anderson RS. Effect of optical defocus on detec-
tion and recognition of vanishing optotype letters in the fovea and
periphery. Invest Ophthalmol Vis Sci. 2012;53:7063–7070.
16. Thibos LN, Cheney FE, Walsh DJ. Retinal limits to the detection and
225resolution of gratings. J Opt Soc Am A. 1987;4:1524–1529.
17. Thibos LN, Walsh DJ, Cheney FE. Vision beyond the resolution limit:
aliasing in the periphery. Vision Res. 1987;27:2193–2197.
18. Demirel S, Anderson RS, Dakin S, et al. Detection and resolution of
vanishing optotype letters in central and peripheral vision. Vision
230Res. 2012;59:9–16.
19. Shah N, Dakin SC, Whitaker HL, et al. Effect of scoring and termina-
tion rules on test-retest variability of a novel high-pass letter acuity
chart. Invest Ophthalmol Vis Sci. 2014;55:1386–1392.
EXPERT REVIEW OF OPHTHALMOLOGY 3
